Trial · NCT07236372
Comparing Standard-Dose and High-Dose Cetirizine for Acute Urticaria
NCT07236372, Not applicable, Recruiting, University of Phayao
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Comparing Standard-Dose and High-Dose Cetirizine for Acute Urticaria. Trials, record NCT07236372. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07236372
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Comparing Standard-Dose and High-Dose Cetirizine for Acute Urticaria
- NCT number
- NCT07236372
- Status
- Recruiting
- Phases
- Not applicable
- Enrollment
- 140 participants, estimated
- Lead sponsor
- University of Phayao
- Conditions
- Acute Urticaria
- Interventions
- Cetirizine 10 mg once daily, Cetirizine 20 mg twice daily, total 40 mg/day
- First posted
- 2025-11-19
- Last updated
- 2026-10-05
Source ClinicalTrials.gov
Registered outcomes5
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Time to Resolution of Acute Urticaria Symptoms | From Day 0 (first dose) to Day 7 or until complete symptom resolution, whichever occurs first. | The time from the first dose of study medication to the complete resolution of acute urticaria symptoms, defined as the absence of hives and an itch score of 0 for at least 24 consecutive hours. Symptom status will be assessed using patient-reported daily symptom diaries and validated scoring tools. |
| Primary | Change in Urticaria Activity Score From Baseline | Baseline to Day 7 | The change in total UAS7 score from baseline to Day 7, based on daily patient-reported wheal and itch scores collected in symptom diaries. |
| Secondary | Use of Systemic Corticosteroids as Rescue Medication | Day 0 to Day 7 | The proportion of participants requiring systemic corticosteroids due to persistent or worsening acute urticaria symptoms despite taking the assigned study medication. |
| Secondary | Change in Dermatology Life Quality Index (DLQI) | Baseline to Day 7 | The change in Dermatology Life Quality Index (DLQI) from baseline to Day 7 to assess the clinical response and quality of life impact of treatment. |
| Secondary | Incidence and Characteristics of Adverse Events | Day 0 to Day 7 and Week 6 follow-up | Number, type, and severity of adverse events occurring during treatment with standard-dose versus high-dose cetirizine. Adverse events may include sedation, dizziness, or other treatment-related symptoms. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers5
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07236372
GET https://conductscience.org/api/trials/v1/NCT07236372/registered